<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated a 16-month-old girl with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts subtype, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> by FAB classification) that developed into <z:hpo ids='HP_0011009'>acute</z:hpo> megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL-M7) </plain></SENT>
<SENT sid="1" pm="."><plain>The blast cells were positive for CD41 shown by flow cytometry and for platelet peroxidase by electron microscopy </plain></SENT>
<SENT sid="2" pm="."><plain>Cytogenetically, five kinds of abnormal karyotypes were apparent at the initial visit and karyotypic progression (<z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e>) was also evident </plain></SENT>
<SENT sid="3" pm="."><plain>These karyotypes were considered to be derived from the putative original clone, 48,XX, +6, +21 </plain></SENT>
<SENT sid="4" pm="."><plain>The observed karyotypes were considered 50,XX, +4,add(4)(q31), +6,add(7)(p22),add(10)(q24),add(12)(q11), +20, +21, + mar[karyotype A];48,XX,add(4)(q31), +6,add(10)(q24),add(12)(q11), +21 [karyotype B];48,XX, +6,t(6;13)(p23;q14), +21 [karyotype C];51,XX, +X, t(6;13)(p23;q14), + der(6)t(6;13)(p23;q14), +21, +21, + mar [karyotype D]; and 49,XX, +X, -3,t(6;13)(p23;q14), +der(6)t(6;13)(p23;q14), -12, +21, +21, + mar [karyotype E] </plain></SENT>
<SENT sid="5" pm="."><plain>It seems karyotypes B and C were derived from the putative clone; karyotype B developed into karyotype A; and karyotype C developed into karyotype E through karyotype D </plain></SENT>
<SENT sid="6" pm="."><plain>After development of ANLL-M7, the cytogenetic study showed a karyotype with further karyotypic progression </plain></SENT>
<SENT sid="7" pm="."><plain>The patient was treated with high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> AraC) followed by allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="8" pm="."><plain>Despite intensive care, she died 3 months after the transplantation </plain></SENT>
</text></document>